Skip to main content
. 2022 Nov 23;12:941454. doi: 10.3389/fonc.2022.941454

Figure 2.

Figure 2

The dynamic changes of serous AFP level over time: AFP dropped to <400 ng/ml after surgical removal of an intrahepatic tumor in June 2019 and sintilimab-bevacizumab biosimilar IBI305–hfIMRT–oxaliplatin combination treatment in February 2022, and continued to decline gradually during the stage of maintenance treatment with sintilimab and bevacizumab biosimilar IBI305.